CUREator+ awards A$13.5M in grants to six Australian health startups
What's the deal? Six Australian biomedical and health technology startups have been awarded a combined A$13.5 million through the second funding round of CUREator+, a non-dilutive commercialisation program delivered by Brandon BioCatalystDealroom has a profile for this one. Try Dealroom → with ANDHealth and supported by Australia's Medical Research Future Fund.
Who got what? Aleris TherapeuticsDealroom has a profile for this one. Try Dealroom →, Frontier Inflammasome Therapeutics, and Luma Bio each received A$2.5 million. Navier MedicalDealroom has a profile for this one. Try Dealroom → received A$2.13 million, NeurotologixDealroom has a profile for this one. Try Dealroom → received A$1.95 million, and WeGuideDealroom has a profile for this one. Try Dealroom → received A$1.945 million.
What are they building? The recipients are developing therapies for inflammatory disease and cancer, AI-enabled cardiac risk markers, a platform for assessing vertigo and dizziness, and digital biomarkers based on wearable, clinical, and patient-generated health data.
Read more: DistilINFO · Brandon BioCatalyst
